Promising
Clemastine: repair myelin in relapsing MS
relapsing MS · Remyelination / oligodendrocyte repair
A controlled phase 2 trial was positive. Phase 2 trials are small and often measure early markers, so this is a signal, not proof.
- Trials
- 2
- Running now
- 1
- Controlled phase 2/3 trials
- 1
- People in controlled trials
- 50
How the verdict was reached
Positive in phase 2 only
| Trial | Phase | Participants | Started | Result | Counted |
|---|---|---|---|---|---|
| ReBUILD | Phase 2 | 50 | 2014 | Met its main goal The primary efficacy endpoint was met with clemastine fumarate treatment, which reduced the latency delay by 1·7 ms/eye (95% CI 0·5-2·9; p=0·0048) when analysing the trial as a crossover. Paper abstract | Counted |
| ReINFORCE | Phase1|phase2 | 44 | 2026 | Still running | Not counted: tested as the comparator |
Counted: 1. Will count later: 0. Not counted: 1.
Lab evidence
Lab studies in animals or cells. Results in animals often do not hold in people, and these studies never change the status of an idea.
Loading lab studies…
Loading reviews and guidelines…
History
- Oct 2026Status changed from Being tested to Promising
- Oct 2026First listed as Being tested
Related hypotheses
Assembled by software from public sources.